))
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
Manage episode 385512912 series 2838329
Innehåll tillhandahållet av VJHemOnc. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av VJHemOnc eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in this disease. Early and accurate diagnosis present a key challenge, and both clinicians and researchers are investigating novel strategies with the aim of improving outcomes for patients.
In this podcast, Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Efstathios Kastritis, MD, University of Athens, Athens, Greece, discuss unmet needs in AL amyloidosis, as well as novel immunotherapy strategies being explored. The experts also highlight the prevalence of clonal hematopoiesis of indeterminate potential (CHIP) in this disease setting.
200 episoder
Dela
